Chen Bairu, He Jie, Tang Jingli, Liu Xiaoqin
Department of Orthopedics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
BMC Musculoskelet Disord. 2025 Jun 2;26(1):541. doi: 10.1186/s12891-025-08731-8.
The purpose of this study was to evaluate the occurrence and potential causes of residual back pain following percutaneous vertebral augmentation (percutaneous vertebroplasty/percutaneous kyphoplasty) in patients with osteoporotic vertebral compression fracture.
To investigate the occurrence and risk factors of residual back pain, a comprehensive search was conducted in several databases including PubMed, Web of Science, Embase, Cochrane Library, China Knowledge Resource Integrated Database (CNKI), Chinese Biomedical Database (CBM), Wanfang Database, and Weipu Database (VIP) from the inception until October 10, 2023. After applying inclusion and exclusion criteria, the articles were filtered. The quality of the included studies was assessed independently by two investigators. Stata18.0 was used for the meta-analysis.
In total, 1900 articles were screened, and data from 13 studies was used in the meta-analysis. After percutaneous vertebral augmentation for patients with osteoporotic vertebral compression fracture, the occurrence of residual back pain was 19% (95% confidence interval 14-23%, I = 96.6%, P < 0.001). The risk of residual back pain was increased by lower bone mineral density (OR = 5.56, 95%CI 3.83-8.09, P < 0.001), presence of intravertebral vacuum cleft (OR = 3.52, 95% CI 2.07-6.01, P < 0.001), unsatisfactory distribution of bone cement (OR = 2.79, 95% CI 2.05-3.81, P < 0.001), occurrence of recurrent fracture (OR = 4.34, 95%CI 2.75-6.84, P < 0.001), thoracolumbar fascia injury (OR = 3.21, 95% CI 1.91-5.40, P < 0.001), inadequate volume of bone cement injection (OR = 5.58, 95% CI 1.97-15.84, P = 0.001), and nonunion of fracture (OR = 4.67, 95%CI 2.00-10.88, P < 0.001). Furthermore, the rate of recovery in vertebral height (OR = 0.52 (95%CI 0.32-0.85, P = 0.009) may serve as a protective element.
There was a 19% prevalence of residual back pain among osteoporotic vertebral compression fracture patients with percutaneous vertebral augmentation. Patients with osteoporotic vertebral compression fracture may experience residual back pain after percutaneous vertebral augmentation due to a combination of intravertebral vacuum cleft, unsatisfactory bone cement distribution, recurrent fracture, thoracolumbar fascia injury, insufficient bone cement injection volume, fracture nonunion, bone mineral density, and vertebral height recovery rate.
本研究旨在评估骨质疏松性椎体压缩骨折患者经皮椎体强化术(经皮椎体成形术/经皮后凸成形术)后残留背痛的发生率及潜在原因。
为调查残留背痛的发生率及危险因素,从数据库建立至2023年10月10日,在多个数据库进行全面检索,包括PubMed、Web of Science、Embase、Cochrane图书馆、中国知网(CNKI)、中国生物医学文献数据库(CBM)、万方数据库和维普数据库(VIP)。应用纳入和排除标准后,对文章进行筛选。由两名研究人员独立评估纳入研究的质量。使用Stata18.0进行荟萃分析。
共筛选出1900篇文章,13项研究的数据用于荟萃分析。骨质疏松性椎体压缩骨折患者经皮椎体强化术后,残留背痛的发生率为19%(95%置信区间14 - 23%,I² = 96.6%,P < 0.001)。较低的骨密度(OR = 5.56,95%CI 3.83 - 8.09,P < 0.001)、椎体内真空裂隙的存在(OR = 3.52,95%CI 2.07 - 6.01,P < 0.001)、骨水泥分布不满意(OR = 2.79,95%CI 2.05 - 3.81,P < 0.